Home / Resource Library / Fixed-Duration Venetoclax/Obinutuzumab Provides Robust PFS Benefit in Untreated CLLFixed-Duration Venetoclax/Obinutuzumab Provides Robust PFS Benefit in Untreated CLL EHA 2022